Carcinoembryonic Antigen, Human (CEA, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5, CEACAM5, CD66e, CD66e Antigen, DKFZp781M2392, Meconium Antigen 100) BioAssay(TM) ELISA Kit

Carcinoembroyonic antigen (CEA) is a cell-surface 200kD glycoprotein. In 1969, it was reported that plasma CEA was elevated in 35 of 36 patients with adenocarcinoma of the colon and that CEA titers decreased after successful surgery. Normal levels were observed in all patients with other forms of cancer or benign diseases. Subsequent studies have not confirmed these initial findings, and it is now understood that elevated levels of CEA are found in many cancers. Increased levels of CEA are observed in more than 30% of patients with cancer of the lung, liver, pancreas, breast, colon, head or neck, bladder, cervix, and prostate. Elevated plasma levels are related to the stage and extent of the disease, the degree of differentiation of the tumor, and the site of metastasis. CEA is also found in normal tissue.\n\nSample Type: \nSerum\n\nIntended Use: \nFor the quantitative research of the Cancer Antigen CEA concentration in human serum.\n\nTest Principle: \nThe CEA ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a monoclonal antibody directed against a distinct antigenic determinant on the intact CEA molecule is used for solid phase immobilization (on the microtiter wells). A goat anti-CEA antibody conjugated to horseradish peroxidase (HRP) is in the antibody-enzyme conjugate solution. The test sample is allowed to react simultaneously with the two antibodies, resulting in the CEA molecules being sandwiched between the solid phase and enzyme-linked antibodies. After a 1 hour incubation at room temperature, the wells are washed with water to remove unbound labeled antibodies. A solution of TMB Reagent is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution changing the color to yellow. The concentration of CEA is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.\n\nKit Components:\nAntibody-coated microtiter plate 1x96 wells.\n\nStandards \n0ng/ml\n3ng/ml\n12ng/ml\n30ng/ml\n60ng/ml\n120ng/ml CEA. \n1ml each, ready to use Enzyme Conjugate Reagent \n\nTMB Reagent (One-Step) 1x13ml \n\nStop Solution (1N HCl), 1x11 ml\n\nStorage and Stability:\nStore all components at 4 degrees C. Stable for at least 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C1300-05H

Size

1Kit

References

1 Engall, E., Methods in Enzymology, Volume 70, Van Vunakis, H. and Langone, J. J. (eds.), Academic Press, New York, 419-492(1980). 2 Uotila, M., Ruoslahti, E. and Engvall, E., J. lmmunol. Methods, 42,\n11-15 (1981). 3 Gold P, Freedman S O. Demonstration of tumor specific antigen in human colonic carcinoma by immunologic tolerance and absorption techniques. J Exp Med 1965;127:439-462. 4 Thompson D P M, Krupey J, Freedman S O, et al. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci USA 1969;64:161-167. 5 Schwartz M K. Tumor markers in diagnosis and screening. In: Ting S W, Chen J S, Schwartz M K, eds. Human tumor markers, Amsterdam: Elsevier Science, 1987;3-16. 6 Zamcheck N. and Martin E.W. Sequential Carcinoembryonic Antigen Levels in Pancreatic Cancer: Some Clinical Correlations. Cancer 1981;47:1620-1627. 7 Mughal A.W., Hortobagyi G. N., Fritsche H.A., Buzdar A.U. Yap HY., and Blumenschein G.R. Serial Plasma Carcinoembryonic Antigen Measurements During Treatment of Metastatic Breast Cancer. JAMA 1983; 259:1881-1886. 082007 CEA (ng/ml) Absorbance (450 nm)\n0 0.051 3 0.191 12 0.567 30 1.224 60 1.951 120 2.889 0 0.5 1 1.5 2 2.5 3 3.5 0 50 100 150 Conc. of CEA (ng/ml) Absorbance (450 nm),